ASTEX PHARMACEUTICALS, INC (SUPG) financial statements (2020 and earlier)

Company profile

Business Address 4140 DUBLIN BLVD
DUBLIN, CA 94568
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments138
Cash and cash equivalents15
Short-term investments123
Receivables1
Prepaid expense and other current assets2
Income taxes receivable5
Total current assets:147
Noncurrent Assets
Property, plant and equipment6
Long-term investments and receivables0
Long-term investments0
Intangible assets, net (including goodwill)121
Goodwill47
Intangible assets, net (excluding goodwill)75
Prepaid expense and other noncurrent assets2
Total noncurrent assets:129
TOTAL ASSETS:275
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14
Accounts payable9
Accrued liabilities1
Employee-related liabilities4
Deferred tax liabilities3
Other undisclosed current liabilities2
Total current liabilities:20
Noncurrent Liabilities
Liabilities, other than long-term debt4
Deferred tax liabilities, net4
Other undisclosed noncurrent liabilities15
Total noncurrent liabilities:19
Total liabilities:38
Stockholders' equity
Stockholders' equity attributable to parent, including:237
Common stock0
Additional paid in capital565
Accumulated other comprehensive loss(2)
Accumulated deficit(327)
Warrants and rights outstanding0
Other undisclosed stockholders' equity attributable to parent(0)
Total stockholders' equity:237
TOTAL LIABILITIES AND EQUITY:275

Income statement (P&L) ($ in millions)

12/31/2012
Gross profit:83
Operating expenses(90)
Operating loss:(7)
Nonoperating expense(0)
Investment income, nonoperating(0)
Other undisclosed income from continuing operations before equity method investments, income taxes3
Loss from continuing operations before income taxes:(5)
Income tax benefit13
Net income available to common stockholders, diluted:8

Comprehensive Income ($ in millions)

12/31/2012
Net income:8
Other comprehensive income5
Comprehensive income, net of tax, attributable to parent:13

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: